Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP)‘s stock had its “buy” rating restated by stock analysts at Needham & Company LLC in a research note issued on Thursday. They presently have a $25.00 price target on the stock. Needham & Company LLC’s price target points to a potential upside of 129.78% from the stock’s current price.
The analysts wrote, “Aquinox reported 3Q17 financial results this week. Phase 3 LEADERSHIP 301 trial of rosiptor continues to enroll pts and company continues to guide for top-line results in 3Q18. We expect a positive outcome based on Phase 2 data and reiterate BUY.””
AQXP has been the subject of several other research reports. BidaskClub upgraded Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Canaccord Genuity set a $22.00 target price on Aquinox Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 8th. Zacks Investment Research upgraded Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Thursday, August 10th. Cantor Fitzgerald restated a “buy” rating and set a $28.00 target price on shares of Aquinox Pharmaceuticals in a research report on Thursday. Finally, ValuEngine lowered Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $22.80.
Shares of Aquinox Pharmaceuticals (AQXP) traded up $0.03 on Thursday, reaching $10.88. The company’s stock had a trading volume of 45,900 shares, compared to its average volume of 86,608. Aquinox Pharmaceuticals has a fifty-two week low of $10.68 and a fifty-two week high of $19.97.
TRADEMARK VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2017/11/12/needham-company-llc-reiterates-buy-rating-for-aquinox-pharmaceuticals-inc-aqxp.html.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC purchased a new stake in shares of Aquinox Pharmaceuticals during the third quarter valued at approximately $194,000. Sphera Funds Management LTD. increased its position in shares of Aquinox Pharmaceuticals by 21.7% during the third quarter. Sphera Funds Management LTD. now owns 75,535 shares of the company’s stock valued at $1,072,000 after acquiring an additional 13,450 shares during the last quarter. Nexthera Capital LP purchased a new stake in shares of Aquinox Pharmaceuticals during the second quarter valued at approximately $1,276,000. Vanguard Group Inc. increased its position in shares of Aquinox Pharmaceuticals by 6.6% during the second quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock valued at $3,974,000 after acquiring an additional 17,455 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of Aquinox Pharmaceuticals by 3.3% during the second quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock valued at $1,171,000 after acquiring an additional 2,691 shares during the last quarter. 95.15% of the stock is owned by institutional investors.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.